Gregory Abel.

Gregory Abel, MD, MPH

Professor of Medicine, HMS
Co-Chair, Dana-Farber Ethics Advisory Committee
Member, HMS Center for Bioethics

Gregory Abel, MD, MPH is an outcomes researcher and hematologic oncologist at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School. He helps run DFCI’s Older Adult Hematologic Malignancy (OHM) geriatric hematology research program, serves as Co-Chair of the DFCI Ethics Advisory Committee, and directs DFCI’s Clinical Ethics Service. The Abel research lab applies health services research methods to understand the experiences of patients with blood cancers and develop interventions to improve their care. Dr. Abel is also interested in evaluating how cancer and its therapies affect outcomes such as function and quality of life. Through his work and collaboration with researchers in oncology, hematology, geriatrics, bioethics, and energy balance, he aims to ameliorate the impact of hematologic malignancies and their treatment from diagnosis to the end of life.

Publications View
Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review.
Authors: Authors: DuMontier C, Loh KP, Bain PA, Silliman RA, Hshieh T, Abel GA, Djulbegovic B, Driver JA, Dale W.
J Clin Oncol
View full abstract on Pubmed
Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved Caregivers.
Authors: Authors: Henckel C, Revette A, Huntington SF, Tulsky JA, Abel GA, Odejide OO.
J Pain Symptom Manage
View full abstract on Pubmed
An Action Plan for Environmentally Sustainable Cancer Care.
Authors: Authors: Hantel A, Abel GA.
JAMA Oncol
View full abstract on Pubmed
Patient-hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study.
Authors: Authors: Loh KP, Xu H, Back A, Duberstein PR, Gupta Mohile S, Epstein R, McHugh C, Klepin HD, Abel G, Lee SJ, El-Jawahri A, LeBlanc TW.
Cancer
View full abstract on Pubmed
Goals of care discussions for patients with blood cancers: Association of person, place, and time with end-of-life care utilization.
Authors: Authors: Odejide OO, Uno H, Murillo A, Tulsky JA, Abel GA.
Cancer
View full abstract on Pubmed
Patient-preferred outcomes measurement after post-mastectomy radiation therapy and immediate reconstruction.
Authors: Authors: Punglia RS, Ortiz Pimentel S, Cronin AM, Frank ES, Bellon JR, Abel GA, Uno H, Wong JS.
Breast J
View full abstract on Pubmed
Patients as experts: characterizing the most relevant patient-reported outcomes after hematopoietic cell transplantation.
Authors: Authors: Solle JC, Steinberg A, Marathe P, Gray TF, Emmert A, Abel GA.
Bone Marrow Transplant
View full abstract on Pubmed
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.
Authors: Authors: Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeg HJ, Epling-Burnette PK.
Leuk Lymphoma
View full abstract on Pubmed
Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission.
Authors: Authors: Slavin SD, Fenech A, Jankowski AL, Abel GA, Brunner AM, Steensma DP, Fathi AT, DeAngelo DJ, Wadleigh M, Hobbs GS, Amrein PC, Stone RM, Temel JS, El-Jawahri A.
Cancer
View full abstract on Pubmed
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.
Authors: Authors: El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, Fathi A, Steensma DP, LeBlanc TW, Horick NK, DeAngelo DJ, Wadleigh M, Hobbs G, Foster J, Brunner AM, Amrein P, Stone RM, Temel JS, Greer JA.
Leukemia
View full abstract on Pubmed